History of U.S. military contributions to the study of viral hemorrhagic fevers

Military Medicine

Volumn 170, Issue 4 SUPPL., 2005, Pages 77-91

  Thomas, Stephen J ^a   Lawler, James V ^b   Endy, Timothy P ^c  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DNA VACCINE; RIBAVIRIN; YELLOW FEVER VACCINE;

ARBOVIRUS; ARENAVIRUS; BLEEDING; BLOOD CLOTTING DISORDER; CELL DAMAGE; CHIKUNGUNYA ALPHAVIRUS; CLINICAL TRIAL; CONFERENCE PAPER; CRUSH SYNDROME; DEATH; DENGUE; ENCEPHALITIS; EPIDEMIC; FILOVIRUS; GENETIC ORGANIZATION; GEOGRAPHIC DISTRIBUTION; HEMORRHAGIC FEVER; HUMAN; IMMUNE RESPONSE; LASSA FEVER; MILITARY MEDICINE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; SHOCK; SIDE EFFECT; UNITED STATES; VIRUS TRANSMISSION; YELLOW FEVER;

EID: 17444363367     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.170.4S.77     Document Type: Conference Paper

References (263)

1. Domingo E, Escarmis C, Sevilla N, et al: Basic concepts in RNA virus evolution. FASEB J 1996; 10: 859-64.
2. Duarte EA, Novella IS, Weaver SC, et al: RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agent Dis 1994; 3: 201-14.
3. Domingo E, Escarmis C, Sevilla N, Martinez MA: Population dynamics and molecular evolution of RNA viruses. In: Factors in the Emergence of Arbovirus Diseases, pp 273-8. Edited by Saluzzo JF, Dodet B. Paris, France, Elsevier, 1997.
4. Gubler DJ: Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11: 480-96.
5. Gibbons RV, Vaughn DW: Dengue: an escalating problem. BMJ 2002; 324: 1563-6.
6. Halstead SB: Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239: 476-81.
7. Rawlings JA, Hendricks KA, Burgess CR, et al: Dengue surveillance in Texas, 1995. Am J Trop Med Hyg 1998; 59: 95-9.
8. Gill J, Stark LM, Clark GG: Dengue surveillance in Florida. 1997-98. Emerg Infect Dis 2000; 6: 30-5.
9. Travel Medicine Program: Dengue fever in Hawaii. Available at http://www.hc-sc.gc.ca/pphb-dgspsp/tmp-pmv/2001/df-hawaii101_e.html: accessed September 21, 2004.
10. Innis BL, Eckels KH: Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003; 69: 1-4.
11. Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10: 100-3.
12. Bielefeldt Ohmann H: Pathogenesis of dengue virus diseases: missing pieces in the jigsaw. Trends Microbiol 1997; 5: 409-13.
13. Henchal EA, Putnak JR: The dengue viruses. Clin Microbiol Rev 1990; 3: 376-96.
14. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB: Phylogeny of the genus Flavivirus. J Virol 1998; 72: 73-83.
15. Goncalvez AP, Escalante AA, Pujol FH, et al: Diversity and evolution of the envelope gene of dengue virus type 1. Virology 2002; 303: 110-9.
16. Chungue E, Cassar O, Drouet MT, et al: Molecular epidemiology of dengue-1 and dengue-4 viruses. J Gen Virol 1995; 76: 1877-84.
17. Chu MC, O'Rourke EJ, Trent DW: Genetic relatedness among structural protein genes of dengue 1 virus strains. J Gen Virol 1989; 70: 1701-12.
18. Monath TP, Wands JR, Hill LJ, et al: Geographic classification of dengue-2 virus strains by antigen signature analysis. Virology 1986; 154: 313-24.
19. Deubel V, Nogueira RM, Drouet MT, Zeller H, Reynes JM, Ha DQ: Direct sequencing of genomic cDNA fragments amplified by the polymerase chain reaction for molecular epidemiology of dengue-2 viruses. Arch Virol 1993; 129: 197-210.
20. Chungue E, Deubel V, Cassar O, Laille M, Martin PMV: Molecular epidemiology of dengue 3 viruses and genetic relatedness among dengue 3 strains isolated from patients with mild or severe form of dengue fever in French Polynesia. J Gen Virol 1993; 74: 2765-70.
21. Chow VTK, Seah CLK, Chan YC: Comparative analysis of NS3 sequences of temporally separated dengue 3 virus strains isolated from Southeast Asia. Intervirology 1994; 37: 252-8.
22. Lanciotti RS, Lewis JG, Gubler DJ, Trent DW: Molecular evolution and epidemiology of dengue-3 viruses. J Gen Virol 1994; 75: 65-75.
23. Usuku S, Castillo L, Sugimoto C, Noguchi Y, Yogo Y, Kobayashi N: Phylogenetic analysis of dengue-3 viruses prevalent in Guatemala during 1996-1998. Arch Virol 2001; 146: 1381-90.
24. Henchal EA, Repik PM, McCown JM, Brandt WE: Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean. Am J Trop Med Hyg 1986; 35: 393-400.
25. Lanciotti RS, Gubler DJ, Trent DW: Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol 1997; 78: 2279-84.
26. Halstead SB: Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970; 42: 350-62.
27. Halstead SB: Consideration of possible immunologic mechanisms in the etiology of dengue hypersensitivity disease. Bull All Indian Inst Med Sci 1969; 3: 20-7.
28. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al: Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong. Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120: 653-69.
29. Green S, Vaughn DW, Kalayanarooj S, et al: Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 1999; 179: 755-62.
30. Russell PK, Chiewsilp D, Brandt WE: Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses. J Immunol 1970; 105: 838-45.
31. Russell PK, Udomsakdi S, Halstead SB: Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol 1967; 20: 103-8.
32. Burke D: Dengue haemorrhagic fever: a pathological study. Trans R Soc Trop Med Hyg 1968; 625: 682-92.
33. Innis BL: Antibody responses to dengue virus infection. In: Dengue and Dengue Hemorrhagic Fever. pp 221-43. Edited by Gubler DJ, Kuno G. Wallingford, UK, CAB International, 1997.
34. Vaughn DW, Green S, Kalayanarooj S, et al: Dengue in the early febrile phase: vlremia and antibody responses. J Infect Dis 1997; 176: 322-30.
35. Vaughn DW, Green S, Kalayanarooj S, et al: Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181: 2-9.
36. Halstead SB, Nimmannitya S, Margiotta MR: Dengue and chikungunya virus infection in man in Thailand, 1962-1964. II. Observations on disease in outpatients. Am J Trop Med Hyg 1969; 18: 972-83.
37. Halstead SB, Chow J, Marchette NJ: Immunologic enhancement of dengue virus replication. Nature New Biol 1973; 243: 24-6.
38. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L: Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42: 179-84.
39. Morens DM: Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19: 500-12.
40. Twiddy SS, Holmes EC: The extent of homologous recombination in members of the genus Flavivirus. J Gen Virol 2003; 84: 429-40.
41. Gubler DJ, Sather GE, Kuno G, Cabral JR: Dengue 3 virus transmission in Africa. Am J Trop Med Hyg 1986; 35: 1280-4.
42. Bravo JR, Guzman MG, Kouri GP: Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987; 81: 816-20.
43. Ehrenkranz NJ, Ventura AK, Cuadrado RR, Pond WL, Porter JE: Pandemic dengue in Caribbean countries and the Southern United States: past, present and potential problems. N Engl J Med 1971; 285: 1460-9.
44. Trofa AF, DeFraites RF, Smoak BL, et al: Dengue fever in U.S. military personnel in Haiti. JAMA 1997; 277: 1546-8.
45. Gambel JM, Drabick JJ, Martinez-Lopez L: Medical surveillance of multinational peacekeepers deployed in support of the United Nations Mission in Haiti, June-October 1995. Int J Epidemiol 1999; 28: 312-8.
46. Halstead SB, Streit TG, Lafontant JG, et al: Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65: 180-3.
47. Kaplan JE, Eliason DA, Moore M, et al: Epidemiologic investigations of dengue infection in Mexico, 1980. Am J Epidemiol 1983; 117: 335-43.
48. Strickman D, Sithiprasasna R, Kittayapong P, Innis BL: Distribution of dengue and Japanese encephalitis among children in rural and suburban Thai villages. Am J Trop Med Hyg 2000; 63: 27-35.
49. George R: Dengue haemorrhagic fever in Malaysia: a review. Southeast Asian J Trop Med Public Health 1987; 18: 278-3.
50. Halstead SB, Nimmannitya S, Cohen SN: Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42: 311-28.
51. Kabra SK, Jain Y, Pandey RM, et al: Dengue haemorrhagic fever in children in the 1996 Delhi epidemic. Trans R Soc Trop Med Hyg 1999; 93: 294-8.
52. Shekhar KC, Huat OL: Epidemiology of dengue/dengue hemorrhagic fever in Malaysia: a retrospective epidemiological study 1973-1987. I. Dengue hemorrhagic fever (DHF). Asia Pac J Public Health 1992; 6: 15-25.
53. Simmons JS: Dengue fever. Am J Trop Med 1931; 11: 77-102.
54. Reed D, Maguire T, Mataika J: Type 1 dengue with hemorrhagic disease in Fiji: epidemiologic findings. Am J Trop Med Hyg 1977; 26: 784-91.
55. McCoy OR, Sabin AB: Dengue. In: Preventive Medicine in World War II: Communicable Diseases: Arthropodborne Diseases Other than Malaria, pp 29-62. Edited by Coates JB, Hoff EC, Hoff PM. Washington, DC, Office of the Surgeon General, Department of the Army, 1946.
56. Nisalak A, Endy TP, Nimmannitya S, et al: Serorype-specific dengue virus circulation and dengue disease in Bangkok, Thailand, from 1973 to 1999. Am J Trop Med Hyg 2003; 68: 191-202.
57. Kouri GP, Guzman MG, Bravo JR, Triana C: Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ 1989; 67: 375-80.
58. Thisyakorn U, Nimmannitya S: Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993; 16: 295-7.
59. Rush B: An Account of the Bilious Remitting Fever, as It Appeared in Philadelphia, in the Summer and Autumn of the Year 1780: Medical Inquires and Observations, pp 89-100. Philadelphia, PA, Prichard and Hall, 1789.
60. Centers for Disease Control and Prevention: Epidemiologic notes and reports dengue fever among U.S. military personnel: Haiti, September-November. 1994. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00033605.htm; accessed September 21, 2004.
61. Sharp TW, Wallace MR, Hayes CG, et al: Dengue fever in U.S. troops during Operation Restore Hope, Somalia. 1992-1993. Am J Trop Med Hyg 1995; 53: 89-94.
62. Kanesa-thasan N, Iacono-Connors L, Magill A, et al: Dengue serotypes 2 and 3 in U.S. Forces in Somalia. Lancet 1994; 343: 678.
63. Deller JJ, Russell PK, Binh L: An analysis of fevers of unknown origin in American soldiers in Vietnam. Ann Intern Med 1967; 66: 1129-43.
64. Colwell EJ, Brown JD, Russell PK, Boone SC, Legters LJ, Catino D: Investigations on acute febrile illness in American servicemen in the Mekong delta of Vietnam. Milit Med 1969; 134: 1409-14.
65. Asburn PM, Craig CF: Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907; 4: 440-75.
66. Graham H: The dengue: a study of its pathology and mode of propagation. J Trop Med 1903.
67. Deleted in proof.
68. Ashburn PM, Craig CF: Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907; 4: 440-75.
69. Reed W, Carroll J, Agramonte A: The etiology of yellow fever: an additional note. JAMA 1901; 36: 431-40.
70. Siler JF, Hall MW, Hitchens AP: Dengue: its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J Sci 1926; 29: 1-304.
71. Hotta S: Experimental studies on dengue. I. Isolation, identification and modification of the virus. J Infect Dis 1952; 90: 1-9.
72. Hammon WM, Rudnick A, Sather GE: Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 1960; 131: 1102-3.
73. Halstead SB, Yamarat C, Scanlon JE: The Thai hemorrhagic fever epidemic of 1962: a preliminary report. J Med Assoc Thai 1963; 46: 449-62.
74. Hayes CG, Manaloto CR, Gonzales A, Ranoa CP: Dengue infections in the Philippines: clinical and virological findings in 517 hospitalized patients. Am J Trop Med Hyg 1988; 39: 110-6.
75. Hayes CG, O'Rourke TF, Fogelman V, Leavengood DD, Crow G, Albersmeyer MM: Dengue fever in American military personnel in the Philippines: clinical observations on hospitalized patients during a 1984 epidemic. Southeast Asian J Trop Med Public Health 1989; 20: 1-8.
76. Endy TP, Chunsuttiwat S, Nisalak A, et al: Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156: 40-51.
77. Endy TP, Nisalak A, Chunsuttiwat S, et al: Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156: 52-9.
78. Simmons JS, St John JH, Reynolds FHK: Experimental studies of dengue. Philippine J Sci 1931; 44: 1-252.
79. Schlesinger RW, Gordon I, Frankel JW, Winter JW, Patterson PR, Dorrance WR: Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 1956; 77: 352-64.
80. Sabin AB, Schlesinger RW: Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101: 640-2.
81. Wisseman CL, Sweet BH, Rosenzweig EC, Eylar OR: Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963; 12: 620-3.
82. Halstead SB, Eckels KH, Putvatana R, Larsen LK, Marchette NJ: Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33: 679-83.
83. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A: Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 1987; 65: 189-95.
84. Bhamarapravati N, Yoksan S: Study of bivalent dengue vaccine in volunteers. Lancet 1989; 1: 1077.
85. Bhamarapravati N, Yoksan S: Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18(Suppl 2): 44-7.
86. Vaughn DW, Hoke CH, Yoksan S, et al: Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 1996; 14: 329-36.
87. Kanesa-thasan N, Sun W, Kim-Ahn G, et al: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19: 3179-88.
88. Sabchareon A, Lang J, Chanthavanich P, et al: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66: 264-72.
89. Putnak R, Barvir DA, Burrous JM, et al: Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174: 1176-84.
90. Simmons M, Murphy GS, Hayes CG: Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001; 65: 159-61.
91. Raviprakash K, Marques E, Ewing D, et al: Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-cerebrospinal fluid. Virology 2001; 290: 74-82.
92. Putnak R, Fuller A, Vanderzanden L, Innis BL, Vaughn DW: Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral prM and E genes. Am J Trop Med Hyg 2003; 68: 469-76.
93. Chang GJ, Davis BS, Hunt AR, Holmes DA, Kuno G: Flavivirus DNA vaccines: current status and potential. Ann NY Acad Sci 2001; 951: 272-85.
94. Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG: Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 2001; 65: 420-6.
95. Raviprakash K, Ewing D, Simmons M, et al: Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-cerebrospinal fluid gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003; 315: 345-52.
96. Raviprakash K, Porter KR, Kochel TJ, et al: Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81: 1659-67.
97. Graham H: Dengue: a study of its mode of propagation and pathology. Med Rec NY 1902; 61: 204-7.
98. Cleland JB, Bradley B, MacDonald W: Further experiments in the etiology of dengue fever. J Hyg 1919; 18: 217-54.
99. Sawada T, Sato H, Sai S: On the experimental dengue infection in man. Nippon Igaku 1943; 3325: 529-31.
100. Misao T: Clinical aspects of dengue fever. Chiryo 1944; 26: 199-218.
101. Taniguchi T, Fujino T, Inoki S, Okuno Y: Studies on the experimental inoculation of dengue fever. Med J Osaka Univ 1951; 2: 1-36.
102. Wisseman CL, Kitaoka M, Tamiya T: Immunological studies with group B arthropod-borne viruses. V. Evaluation of cross-immunity against type 1 dengue fever in human subjects convalescent from subclinical natural Japanese encephalitis virus infection and vaccinated with 17D strain yellow fever vaccine. Am J Trop Med Hyg 1966; 15: 588-600.
103. Eckels KH, Scott RM, Bancroft WH, et al: Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33: 684-9.
104. Innis BL, Eckels KH, Kraiselburd E, et al: Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1988; 158: 876-80.
105. McKee KT, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK: Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36: 435-42.
106. Monath TP: Glad tidings from yellow fever research. Science 1985; 229: 734-5.
107. McCarthy M: A century of the U.S. Army yellow fever research. Lancet 2001; 357: 1772.
108. Barrett ADT, Monath TP: Epidemiology and ecology of yellow fever virus. In: Advances in Virus Research: The Flaviviruses: Detection, Diagnosis and Vaccine Development, pp 291-315. Edited by Monath T, Chambers T. New York, NY, Academic Press, 2003.
109. Scott HH: A History of Tropical Medicine. Baltimore, MD, Williams & Wilkins, 1939.
110. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH: Nucleotide sequence of yellow fever viruses: implications for flavivirus gene expression and evolution. Science 1985; 229: 726-33.
111. Monath T: Yellow fever; an update. Lancet Infect Dis 2001; 1: 11-20.
112. Kerr J: The Clinical Aspects and Diagnosis of Yellow Fever. New York, NY, McGraw-Hill, 1951.
113. World Health Organization: Yellow Fever: Fact Sheet 100. Geneva, Switzerland, World Health Organization, 2001. Available at http://www.who.int/ mediacentre/factsheets/fs100/en; accessed September 21. 2004.
114. Claude Moore Health Sciences Library: The United States Army Yellow Fever Commission (1900-1901). Charlottesville, VA, University of Virginia, 2001. Available at http://yellowfever.lib.virginia.edu/reed/commission.html; accessed September 30, 2004.
115. Lazear JW: Letter from Jesse W. Lazear to Mabel Houston Lazear, July 15, 1900. In: Philip S. Hench Walter Reed Yellow Fever Collection, Claude Moore Health Sciences Library. Available at http://etext.lib.virginia.edu/etcbin/ fever-browse?id=00334001; accessed September 21, 2004.
116. Reed W: Letter from Walter Reed to George M. Sternberg, July 24, 1900. In: Philip S. Hench Walter Reed Yellow Fever Collection, Claude Moore Health Sciences Library. Available at http://etext.lib.virginia.edu/etcbin/fever- browse?id=02064001: accessed September 21, 2004.
117. Reed W, Carroll J, Afgramonte A, Lazear J: The etiology of yellow fever: a preliminary note. In: Proceedings of the Twenty-eighth Annual Meeting of the American Public Health Association, October 22-26, 1900, Indianapolis, IN. Available at http://etext.lib.virginia.edu/healthsci/reed/commission.html#_edn5; accessed September 2004.
118. Reed W: The propagation of yellow fever: observations based on recent researches. In: Senate Document 822, p 99. Available at http://etext.lib. virginia.edu/healthsci/reed/commission.html; accessed September 2004.
119. Theiler M: Yellow Fever, pp 46-136. Edited by Strode G. New York, NY, McGraw-Hill, 1951.
120. Smith H: Yellow Fever, pp 546-628. Edited by Strode G. New York, NY, McGraw-Hill, 1951.
121. Theiler M, Smith HH: The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937; 65: 787-800.
122. Barrett AD: Yellow fever vaccines. Biologicals 1997; 25: 17-25.
123. Monath T: Yellow fever. In: Vaccines, pp 815-80. Edited by Plotkin S, Orenstein W. Philadelphia, PA, WB Saunders, 1999.
124. Monath TP, Cetron MS: Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34: 1369-78.
125. Monath TP, Levenbook I, Soike K, et al: Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000; 74: 1742-51.
126. Guirakhoo F, Arroyo J, Pugachev KV, et al: Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001; 75: 7290-304.
127. Buchenmeier MJ, Bowen MD, Peters CJ: Arenaviridae: the viruses and their replication. In: Fields Virology, pp 1635-68. Edited by Fields BN, Knipe DM, Howley PM, Griffin DE. Philadelphia, PA, Lippincott Williams & Wilkins, 2001.
128. Fulhorst CF, Bennett SG, Milazzo ML, et al: Bear Canyon virus: an arenavirus naturally associated with the California mouse (Peromyscus cctliforracus). Emerg Infect Dis 2002; 8: 717-21.
129. Moncayo AC, Hice CL, Watts DM, et al: Allpahuayo virus: a newly recognized arenavirus (Arenaviridae) from arboreal rice rats (Oecomys bicolor and Oecomys paricola) in northeastern Peru. Virology 2001; 284: 277-86.
130. Peters CJ: Lymphocytic choriomeningitis virus, Lassa virus, and the South American hemorrhagic fevers. In: Mandell, Douglass, and Bennett's Principles and Practice of Infectious Diseases, Ed 5, pp 1855-62. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia, PA, Churchill Livingstone, 2000.
131. Mills JN, Barrera Oro JG, Bressler DS, et al: Characterization of Oliveros virus, a new member of the Tacaribe complex (Arenavirridae: Arenavirus). Am J Trop Med Hyg 1996; 54: 399-404.
132. Tesh RB, Jahrling PB, Salas R, Shope RE: Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg 1994; 50: 452-9.
133. Kastello MD, Eddy GA, Kuehne RW: A rhesus monkey model for the study of Bolivian hemorrhagic fever. J Infect Dis 1976; 133: 57-62.
134. Wagner FS, Eddy GA, Brand OM: The African green monkey as an alternate primate host for studying Machupo virus infection. Am J Trop Med Hyg 1977; 26: 159-62.
135. Eddy GA, Scott SK, Wagner FS, Brand OM: Pathogenesis of Machupo virus infection in primates. Bull World Health Organ 1975; 52: 517-21.
136. McLeod CG, Stookey JL, Eddy GA, Scott K: Pathology of chronic Bolivian hemorrhagic fever in the rhesus monkey. Am J Pathol 1976; 84: 211-24.
137. McLeod CG, Stookey JL, White JD, Eddy GA, Fry GA: Pathology of Bolivian hemorrhagic fever in the African green monkey. Am J Trop Med Hyg 1978; 27: 822-6.
138. Scott SK, Hickman RL, Lang M, Eddy GA, Hilmas DE, Spertzel RO: Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys. Am J Trop Med Hyg 1978; 27: 1232-9.
139. Maiztegui JI, Fernandez NJ, Damilano AJ: Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2: 1216-7.
140. Eddy GA, Wagner FS, Scott SK, Mahlandt BJ: Protection of monkeys against Machupo virus by the passive administration of Bolivian hemorrhagic fever immunoglobulin (human origin). Bull World Health Organ 1975; 52: 723-7.
141. Stephen EL, Jahrling PB: Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet 1979; 1: 268-9.
142. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL: Lassa virus Infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980; 141: 580-9.
143. Frame JD, Jahrling PB, Yalley-Ogunro JE, Monson MH: Endemic Lassa fever in Liberia. II. Serological and virological findings In hospital patients. Trans R Soc Trop Med Hyg 1984; 78: 656-60.
144. McCormick JB, King IJ, Webb PA, et al: Lassa fever: effective therapy with ribavirin. N Engl J Med 1986; 314: 20-6.
145. McKee KT, Mahlandt BG, Maiztegui JI, Green DE, Peters CJ: Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaques. J Med Virol 1987; 22: 99-111.
146. Callis RT, Jahrling PB, DePaoli A: Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 1982; 31: 1038-45.
147. Jahrling PB, Frame JD, Rhoderick JB, Monson MH: Endemic Lassa fever in Liberia. FV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985; 79: 380-4.
148. Niklasson BS, Jahrling PB, Peters CJ: Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay. J Clin Microbiol 1984; 20: 239-44.
149. Stephenson EH, Larson EW, Dominik JW: Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol 1984; 14: 295-303.
150. Frame JD, Jahrling PB, Yalley-Ogunro JE, Monson MH: Endemic Lassa fever in Liberia. II. Serological and virological findings in hospital patients. Trans R Soc Trop Med Hyg 1984; 78: 656-60.
151. Smee DF, Gilbert J, Leonhardt JA, Barnett BB, Huggins JH, Sidwell RW: Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res 1993; 20: 57-70.
152. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB: Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect Immun 1981; 32: 872-80.
153. Kenyon RH, Canonico PG, Green DE, Peters CJ: Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) In guinea pigs. Antimicrob Agents Chemother 1986; 29: 521-3.
154. Kenyon RH, Green DE, Maiztegui JI, Peters CJ: Viral strain-dependent differences in experimental Argentine hemorrhagic fever (Junin virus) infection of guinea pigs. Intervirology 1988; 29: 133-43.
155. Kenyon RH, Green DE, Peters CJ: Effect of immunosuppression on experimental Argentine hemorrhagic fever in guinea pigs. J Virol 1985; 53: 75-80.
156. Kenyon RH, McKee KT, Zack PM, et al: Aerosol infection of rhesus macaques with Junin virus. Intervirology 1992; 33: 23-31.
157. McKee KT, Mahlandt BG, Maiztegui JI, Eddy GA, Peters CJ: Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J Infect Dis 1985; 152: 218-21.
158. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT, Barrera Oro JG: Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987; 134: 5-68.
159. Kenyon RH, Condie RM, Jahrling PB, Peters CJ: Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb Pathog 1990; 9: 219-26.
160. Kenyon RH, Peters CJ: Cytolysis of Junin infected target cells by immune guinea pig spleen cells. Microb Pathog 1986; 1: 453-64.
161. Kenyon RH, Green DE, Eddy GA, Peters CJ: Treatment of Junin virus-infected guinea pigs with immune serum: development of late neurological disease. J Med Virol 1986; 20: 207-18.
162. McKee KT, Huggins JW, Trahan CJ, Mahlandt BG: Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever. Antimicrob Agents Chemother 1988; 32: 1304-9.
163. McKee KT, Oro JG, Kuehne AI, Spisso JA, Mahlandt BG: Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 1993; 48: 403-11.
164. Maiztegui JI, McKee KT, Barrera Oro JG, et al: Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 1998; 177: 277-83.
165. Sanchez AS, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ: Filoviridae: Marburg and Ebola Viruses. In: Fields Virology, pp 1279-304. Edited by Fields BN, Knipe DN, Howley PM, Griffin DE. Philadelphia, PA, Lippincott Williams & Wilkins, 2001.
166. Hart MK: Vaccine research efforts for filoviruses. Int J Parasitol 2003; 33: 583-95.
167. Peters CJ, Le Duc JW: An introduction to Ebola: the virus and the disease. J Infect Dis 1999: 179(Suppl 1): ix-xvi.
168. Borio L, Inglesby T, Peters CJ, et al: Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391-405.
169. Bausch DG, Borchert M, Grein T, et al: Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003; 9: 1531-7.
170. World Health Organization, Communicable Disease Surveillance and Response: Disease outbreaks: Ebola hemorrhagic fever. Available at www.who.int/disease-outbreak-news/disease/A98.4.htm; accessed August 2004.
171. Geisbert T, Jahrling P: Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic. J Clin Pathol 1990; 43: 813-6.
172. Jaax N, Jahrling P, Geisbert T, et al: Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346: 1669-71.
173. Johnson E, Jaax N, White J, Jahrling P: Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995; 76: 227-238.
174. Preston R: The Hot Zone. New York, NY, Random House, 1994.
175. Jahrling PB, Geisbert TW, Dalgard DW, et al: Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990; 335: 502-5.
176. Geisbert T, Rhoderick J, Jahrling P: Rapid identification of Ebola virus and related filoviruses in fluid specimens using indirect immunoelectron microscopy. J Clin Pathol 1991; 44: 521-2.
177. Geisbert T, Jahrling P, Hanes M, Zack P: Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106: 137-52.
178. Rollin PE, Ksiazek TG, Jahrling PB, Haines M, Peters CJ: Detection of Ebola-like viruses by immunofluorescence. Lancet 1990; 336: 1591.
179. Geisbert T, Jahrling P: Differentiation of filoviruses by electron microscopy. Virus Res 1995; 39: 129-50.
180. Deleted in proof.
181. Jaax N, Davis K, Geisbert T, et al: Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120: 140-55.
182. Davis KJ, Anderson AO, Geisbert TW, et al: Pathology of experimental Ebola virus infection in African green monkeys. Arch Pathol Lab Med 1997; 121: 805-19.
183. Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ: Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch Virol 1996; 11(Suppl): 115-34.
184. Ksiazek TG, Rollin PE, Jahrling PB, Johnson E, Dalgard DW, Peters CJ: Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol 1992; 30: 947-50.
185. Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ: ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999; 179(Suppl 1): S192-8.
186. Leirs H, Mills J, Krebs J, et al: Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis 1999; 179(Suppl 1): S155-63.
187. Reiter P, Turell M, Coleman R, et al: Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis 1999; 179(Suppl 1): S148-54.
188. Bray M, Hatfill S, Hensley L, Huggins JW: Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125: 243-53.
189. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J: A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178: 651-61.
190. Connolly B, Steele K, Davis K, et al: Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(Suppl 1): S203-17.
191. Gibb TR, Bray M, Geisbert TW, et al: Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001; 125: 233-42.
192. Maruyama T, Rodriguez LL, Jahrling PB, et al: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73: 6024-30.
193. Chatterjee NK, Samsonoff WA, Balasubramaniam N, Rush-Wilson K, Spargo W, Church TM: Isolation and characterization of adenovirus 5 from the brain of an infant with fatal cerebral edema. Clin Infect Dis 2000; 31: 830-3.
194. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR: Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76: 6408-12.
195. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A: Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251: 28-37.
196. Sullivan NJ, Geisbert TW, Geisbert JB, et al: Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424: 681-4.
197. Vanderzanden L, Bray M, Fuller D, et al: DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246: 134-44.
198. Martin ML, Lindsey-Regnery H, Sasso DR, McCormick JB, Palmer E: Distinction between Bunyaviridae genera by surface structure and comparison with Hantaan virus using negative stain electron microscopy. Arch Virol 1985; 86: 17-28.
199. Arikawa J, Schmaljohn AL, Dalrymple JM, Schmaljohn CS: Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J Gen Virol 1989; 70: 615-24.
200. Pekosz A, Griot C, Nathanson N, Gonzalez-Scarano F: Tropism of Bunyaviruses: evidence for a G1 glycoprotein-mediated entry pathway common to the California serogroup. Virology 1995; 214: 339-48.
201. Bishop D: Genetic potential of bunyaviruses. Curr Top Microbiol Immunol 1979; 86: 1-33.
202. Schmaljohn CS, Hooper JW: Bunyaviridae: the viruses and their replication. In: Fields Virology, pp 1581-602. Edited by Howley PM. Philadelphia, PA, Lippincott Williams & Wilkins, 2001.
203. Vincent MS, Gumperz JE, Brenner MB: Understanding the function of CD1-restricted T cells. Nat Immunol 2003; 4: 517-23.
204. Yang SH, Lee CG, Song MK, Sung YC: Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease. Virology 2000; 268: 132-40.
205. Geimonen E, Neff S, Raymond T, Kocer SS, Gavriolovskaya IN, Mackow ER: Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc Natl Acad Sci USA 2002; 99: 13837-42.
206. Miyamoto H, Morino Y, Hiroi K, et al: An epidemiologic study on rats associated with outbreak of hemorrhagic fever with renal syndrome: comparison with antibodies for two virus strains, Hantaan virus 76-118 strain and newly isolated WKM strain [in Japanese]. Kansenshogaku Zasshi 1987; 61: 633-8.
207. Yashina L, Mishin V, Zdanovskaya N, Schmalhohn C. Ivanov L: A newly discovered variant of a hantavirus in Apodemus peninsulae, far Eastern Russia. Emerg Infect Dis 2001; 7: 912-3.
208. Alexeyev OA, Baranov BA: Puumala virus infection without signs of renal involvement. Scand J Infect Dis 1993; 25: 525-7.
209. Lahdevirta J: The minor problem of hemostatic impairment in nephropathia epidemica, the mild Scandinavian form of hemorrhagic fever with renal syndrome. Rev Infect Dis 1989; 11(Suppl 4): S860-3.
210. Cohen MS: Epidemic hemorrhagic fever revisited. Rev Infect Dis 1982; 4: 992-5.
211. LeDuc JW, Antoniades A, Siamopoulos K: Epidemiological investigations following an outbreak of hemorrhagic fever with renal syndrome in Greece. Am J Trop Med Hyg 1986; 35: 654-9.
212. Yoo KH, Choi Y: Haemorrhagic fever with renal syndrome in Korean children: Korean Society of Pediatric Nephrology. Pediatr Nephrol 1994; 8: 540-4.
213. Bruno P, Hassell LH, Brown J, Tanner W, Lau A: The protean manifestations of hemorrhagic fever with renal syndrome: a retrospective review of 26 cases from Korea. Ann Intern Med 1990; 113: 385-91.
214. World Health Organization: Viral haemorrhagic fevers: report of a WHO expert committee. World Health Organ Tech Rep Ser 1985; 721: 5-126.
215. Yanagihara R, Amyx HL, Lee PW, Asher DM, Gibbs CJ, Gajdusek DC: Experimental hantavirus infection in nonhuman primates. Arch Virol 1988; 101: 125-30.
216. Huggins JW, Hsiang CM, Cosgriff TM, et al: Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164: 1119-27.
217. Arthur RR, Lofts RS, Gomez J, Glass GE, LeDuc JW, Childs JE: Grouping of hantaviruses by small (S) genome segment polymerase chain reaction and amplification of viral RNA from wild-caught rats. Am J Trop Med Hyg 1992; 47: 210-24.
218. Corwin A, Habib M, Olson J, Scott D, Ksiazek T, Watts DM: The prevalence of arboviral, rickettsial, and Hantaan-like viral antibody among schoolchildren in the Nile river delta of Egypt. Trans R Soc Trop Med Hyg 1992; 86: 677-9.
219. Corwin A, Habib M, Watts D, et al: Community-based prevalence profile of arboviral, rickettsial, and Hantaan-like viral antibody in the Nile River Delta of Egypt. Am J Trop Med Hyg 1993; 48: 776-83.
220. Huggins JW: Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11(Suppl 4): S750-61.
221. LeDuc JW, Smith GA, Johnson KM: Hantaan-like viruses from domestic rats captured in the United States. Am J Trop Med Hyg 1984; 33: 992-8.
222. LeDuc JW: Epidemiology of Hantaan and related viruses. Lab Anim Sci 1987; 37: 413-8.
223. LeDuc JW, Childs JE, Glass GE: The hantaviruses, etiologic agents of hemorrhagic fever with renal syndrome: a possible cause of hypertension and chronic renal disease in the United States. Annu Rev Public Health 1992; 13: 79-98.
224. McClain D, Summers P, Harrison S, Schmaljohn A, Schmaljohn C: Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol 2000; 60: 77-85.
225. Schmaljohn CS, Hasty SE, Harrison SA, Dalrymple JM: Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J Infect Dis 1983; 148: 1005-12.
226. Schmaljohn CS, Dalrymple JM: Analysis of Hantaan virus RNA: evidence for a new genus of Bunyaviridae. Virology 1983; 131: 482-91.
227. Schmaljohn CS, Hasty SE, Dalrymple JM, et al: Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science 1985; 227: 1041-4.
228. Schmaljohn CS, Sugiyama K, Schmaljohn AL, Bishop DH: Baculovirus expression of the small genome segment of Hantaan virus and potential use of the expressed nucleocapsid protein as a diagnostic antigen. J Gen Virol 1988; 69: 777-86.
229. Schmaljohn CS, Schmaljohn AL, Dalrymple JM: Hantaan virus M RNA: coding strategy, nucleotide sequence, and gene order. Virology 1987; 157: 31-9.
230. Schmaljohn CS, Lee HW, Dalrymple JM: Detection of hantaviruses with RNA probes generated from recombinant DNA. Arch Virol 1987; 95: 291-301.
231. Schmaljohn CS, Arikawa J, Hasty SE, et al: Conservation of antigenic properties and sequences encoding the envelope proteins of prototype Hantaan virus and two virus isolates from Korean haemorrhagic fever patients. J Gen Virol 1988; 69: 1949-55.
232. Pensiero MN, Jennings GB, Schmaljohn CS, Hay J: Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol 1988; 62: 696-702.
233. Arikawa J, Lapenotiere HF, Iacono-Connors L, Wang ML, Schmaljohn CS: Coding properties of the S and the M genome segments of Sapporo rat virus: comparison to other causative agents of hemorrhagic fever with renal syndrome. Virology 1990; 176: 114-25.
234. Schmaljohn CS. Hasty SE, Dalrymple JM: Preparation of candidate vacciniavectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 1992; 10: 10-3.
235. Schmaljohn C, Vanderzanden L, Bray M, et al: Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol 1997; 71: 9563-9.
236. Schmaljohn C, Hjelle B: Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3: 95-104.
237. Linthicum KJ, Anyamba A, Tucker CJ, Kelley PW, Myers MF, Peters CJ: Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya. Science 1999; 285: 397-400.
238. Meegan JM: Rift Valley fever epizootic in Egypt: description of the epizootic and virological studies. Trans R Soc Trop Med Hyg 1979; 73: 618-23.
239. Peters CJ: Emergence of Rift Valley fever. In: Factors in the Emergence of Arbovirus Diseases, pp 253-64. Edited by Saluzzo JF, Dodet B. Paris, France, Elsevier, 1997.
240. Madani TA, Al-Mazrou YY, Al-Jeffri MH, et al: Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37: 1084-92.
241. Al-Hazmi M, Ayoola EA, Abdurahman M, et al: Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 2003; 36: 245-52.
242. Botros BA, Watts DM, Soliman AK, et al: Serological evidence of dengue fever among refugees, Hargeysa, Somalia. J Med Virol 1989; 29: 79-81.
243. Watts DM, el-Tigani A, Botros BA, et al: Arthropod-borne viral infections associated with a fever outbreak in the northern province of Sudan. J Trop Med Hyg 1994; 97: 228-30.
244. Davies FG, Kilelu E, Linthicum KJ, Pergram RG: Patterns of Rift Valley fever activity in Zambia. Epidemiol Infect 1992; 108: 185-91.
245. Linthicum KJ, Bailey CL, Davies FG, Tucker CJ: Detection of Rift Valley fever viral activity in Kenya by satellite remote sensing imagery. Science 1987; 235: 1656-9.
246. Linthicum KJ, Bailey CL, Tucker CJ, et al: Application of polar-orbiting, meterological satellite data to detect flooding of Rift Valley fever virus vector mosquito habitats in Kenya. Med Vet Entomol 1990; 4: 433-8.
247. Linthicum KJ, Bailey CL, Tucker CJ, et al: Towards real-time prediction of Rift Valley fever epidemics in Africa. Prev Vet Med 1991; 11: 325-34.
248. Dalrymple JM, Schlesinger S, Russell PK: Antigenic characterization of two Sindbis envelope glycoprotetns separated by isoelectric focusing. Virology 1976; 69: 93-103.
249. Mangiafico JA: Chikungunya virus infection and transmission in five species of mosquito. Am J Trop Med Hyg 1971; 20: 642-5.
250. Halstead SB, Udomsakdi S, Singharaj P, Nisalak A: Dengue chikungunya virus infection in man in Thailand, 1962-1964. 3. Clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am J Trop Med Hyg 1969; 18: 984-96.
251. Halstead SB, Udomsakdi S, Scanlon J, Rohitayodhin S: Dengue and chikungunya virus infection in man in Thailand, 1962-1964. V. Epidemiologic observations outside Bangkok. Am J Trop Med Hyg 1969; 18: 1022-33.
252. Halstead SB: Mosquito-borne haemorrhagic fevers of South and South-East Asia. Bull World Health Organ 1966; 35: 3-15.
253. Halstead SB, Udomsakdi S: Vertebrate hosts of chikungunya virus. Bull World Health Organ 1966; 35: 1827.
254. Udomsakdi S, Nisalak A, Halstead SB: Identification of dengue and chikungunya viruses. Bull World Health Organ 1966; 35: 68-9.
255. McClain DJ, Pittman PR, Ramsburg HH, et al: Immunologic interference from sequential administration of live-attenuated alphavirus vaccines. J Infect Dis 1998; 177: 634-41.
256. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C: Production and evaluation of a Formalin-killed chikungunya vaccine. J Immunol 1971; 107: 643-7.
257. Eckels KH, Harrison VR, Hetrick FM: Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol 1970; 19: 321-5.
258. Harrison VR, Binn LN, Randall R: Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg 1967; 16: 786-91.
259. Sabin AB: Research on dengue during World War II. Am. J. Trop Med Hyg. 1952; 1: 30-50.
260. Innis BL, Eckels KH: Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med 2003: 69(Suppl 6): 1-4.
261. Putnak RD, Barvir DA, Burrous JM, et al: Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174: 1176-84.
262. Collected Reports, Commission on Hemorrhagic Fever, AFEB, Army Medical Service Graduate School, Walter Reed Army Medical Center, Washington DC, Vol 1, 1952-1953, Smadel Library Collected, Walter Reed Army Institute of Research, Washington, DC.
263. Earle DP (editor): Symposium on Epidemic Hemorrhagic Fever. Am J Med 1954; 16: 617-90.